Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.GRI · Entity 8336 | Director | September 18, 2025 | September 22, 2025 |
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Director · Chief Executive Officer | September 08, 2017 | September 11, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date September 18, 2025 · Filed September 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2035-09-18 | Direct | 23,605 |
Reported balance
After 2025-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-18 · Grant · Acquired 23,605 · Balance 23,605 F1: Options to purchase 17,621 shares vested in full upon the date of grant and options to purchase 5,984 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 17,621 shares vested in full upon the date of grant and options to purchase 5,984 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.
Matinas BioPharma Holdings, Inc.
Report date September 08, 2017 · Filed September 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,539,416 |
Reported balance
After 2017-09-08 transaction · row 1
1 source rowRow 1 · 2017-09-08 · Purchase · Acquired 5,000 · Balance 3,539,416 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2025 Filed Sep 22, 2025 16:05 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 23,605 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001698966-25-000004 · wk-form4_1758571538.xml · derivative · entry 1 Rongen Roelof · CIK 0001698966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,605 Underlying: Common Stock · 23,605 shares Expires 2035-09-18 F1 · derivative.exercise_date: Options to purchase 17,621 shares vested in full upon the date of grant and options to purchase 5,984 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 08:25 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 5,994 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001824293-25-000141 · wk-form4_1756297500.xml · derivative · entry 1 Rongen Roelof · CIK 0001698966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,994 Underlying: Common Stock · 5,994 shares Expires 2035-08-26 F1 · derivative.exercise_date: Options to purchase 4,044 shares vested in full upon the date of grant and options to purchase 1,950 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 16:58 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 4,527 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001824293-25-000117 · wk-form4_1755205102.xml · derivative · entry 1 Rongen Roelof · CIK 0001698966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,527 Underlying: Common Stock · 4,527 shares Expires 2035-08-13 F1 · derivative.exercise_date: The stock option vests in 4 equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 17:57 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 30,297 | $0.69 Strike: $0.69 | $20,774.65 |
DisclosureSEC source: 0001824293-25-000029 · wk-form4_1737759436.xml · derivative · entry 1 Rongen Roelof · CIK 0001698966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,297 Underlying: Common Stock · 30,297 shares Expires 2035-01-23 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 16:07 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 34,483 | $2.90 Strike: $2.90 | $100,000.70 |
DisclosureSEC source: 0001824293-23-000153 · wk-form4_1692043604.xml · derivative · entry 1 Rongen Roelof · CIK 0001698966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,483 Underlying: Common Stock · 34,483 shares Expires 2033-08-10 F1 · derivative.exercise_date: Vests as to 1/12th of the underlying shares of common stock on the date of grant, then in 11 equal quarterly installments such that the stock option is fully vested on the third annual anniversary of the date of grant. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 13:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock | 5,000 | $1.36 | $6,800.00 |
DisclosureSEC source: 0000905718-17-000829 · rongen_form4sep82017.xml · nonDerivative · entry 1 Rongen Roelof · CIK 0001698966 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,539,416 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.